|
|
|
|
|
|
|
|
|
|
Objective
To examine the value of individual and combinations of ovarian cancer associated blood biomarkers for the discrimination between plasma of patients with type I or II ovarian cancer and disease-free volunteers.Research highlights
► We compared 14 biomarkers to discriminate the plasma samples of healthy volunteers and ovarian cancer patients.► Autoantibodies to p53 and NY-ESO-1 were present in plasma of type II but not type I ovarian cancer patients.
► Combining p53 AAbs with CA125 significantly improved discrimination of plasma of type II cancer patients from that of healthy volunteers.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.